PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.

King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio.

The patent allowance represents a critical milestone in protecting Phio's strategic interest in the Company's INTASYL® platform. PH-894, designed to selectively silence BRD4, is a key regulator of gene expression associated with proliferative and infectious disease.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.